REQUEST A DEMO
Total
USD $0.00
Search more companies

Olix Pharmaceuticals, Inc. (South Korea)

Main Activities: Research and Development in Nanotechnology
Full name: Olix Pharmaceuticals, Inc. Profile Updated: March 17, 2026
Buy our report for this company USD 29.95 Most recent financial data: 2024 Available in: English Download a sample report

Olix Pharmaceuticals, Inc. is based in South Korea. The head office is in Suwon. The enterprise currently operates in the Research and Development in Nanotechnology sector. It was first established on February 26, 2010. It currently has a total number of 69 (2024) employees. In its most recent financial highlights, the company reported a net sales revenue increase of 79.98% in Q3C2025. Its total assets grew by 123.15% over the same period. The net profit margin of Olix Pharmaceuticals, Inc. increased by 198.82% in 2025.

Headquarters
1014, 17, Daehak4-Ro, Yeongtong-Gu, Suwon-Si, Gyeonggi-Do
Suwon; Gyeonggi;

Contact Details: Purchase the Olix Pharmaceuticals, Inc. report to view the information.

Website: http://www.olixpharma.com

Basic Information
Total Employees:
Purchase the Olix Pharmaceuticals, Inc. report to view the information.
Outstanding Shares:
Purchase the Olix Pharmaceuticals, Inc. report to view the information.
Registered Capital:
Purchase the Olix Pharmaceuticals, Inc. report to view the information.
Financial Auditors:
Purchase the Olix Pharmaceuticals, Inc. report to view the information.
Incorporation Date:
February 26, 2010
Key Executives
Purchase this report to view the information.
Chief Executive Officer
Ownership Details
Purchase this report to view the information.
26.4%
Purchase this report to view the information.
5.8%
Purchase this report to view the information.
3.1%
Subsidiaries
Olix Us Inc
올릭스 주식회사
Company Performance
Financial values in the chart are available after Olix Pharmaceuticals, Inc. report is purchased.
Looking for more than just a company report?

EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.

Request a demo of the EMIS service
Key Financial Highlights
Annual growth percentages for latest two years in local currency KRW. Absolute financial data is included in the purchased report.
Net sales revenue
79.98%
Total Operating Revenue
96.42%
Operating Profit
9.26%
EBITDA
9.92%
Net Profit/Loss for the Period
-9.26%
Total Assets
123.15%
Total Equity
748.75%
Operating Profit Margin
209.41%
Net Profit Margin
198.82%
Return on Equity (ROE)
147.82%
Debt / Equity
-272131%
Quick Ratio
7189.95%
Cash Ratio
0.9%

To view more information, Request a demonstration of the EMIS service

Buy this company report
Need ongoing access to company, industry or country information?